Holen Sie sich die Stockscreener-App
32.37
1.01%
-0.30
Schlusskurs vom Vortag:
$32.67
Offen:
$32.85
24-Stunden-Volumen:
212.48K
Relative Volume:
0.07
Marktkapitalisierung:
$200.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.98M
KGV:
-16.68
EPS:
-1.9408
Netto-Cashflow:
$-3.85M
1W Leistung:
-24.70%
1M Leistung:
-32.65%
6M Leistung:
+2,551%
1J Leistung:
+2,407%
1-Tages-Spanne:
$30.67
$33.33
1-Wochen-Bereich:
$30.67
$43.29
52-Wochen-Spanne:
$0.93
$79.02
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Firmenname
Bright Minds Biosciences Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie DRUG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| DRUG | 32.15 | 200.02M | 0 | -4.98M | -3.85M | -1.9408 |
| VRTX | 450.67 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.00 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.51 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.00 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Bright Minds Biosciences Inc Aktie (DRUG) Neueste Nachrichten
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting - The Manila Times
Bright Minds to Present BMB-101 Epilepsy Drug Data at Major AES 2024 Conference | DRUG Stock News - StockTitan
Bright Minds Biosciences participates in a conference call with Truist - Nasdaq
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update - GlobeNewswire Inc.
RA Capital Management, L.P. Acquires New Stake in Bright Minds B - GuruFocus.com
When (DRUG) Moves Investors should Listen - Stock Traders Daily
Cormorant Asset Management's Strategic Acquisition of Bright Min - GuruFocus.com
Bright Minds Biosciences Secures $35 Million Investment - Yahoo Finance
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement - ForexTV.com
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? - Benzinga
McMillan advised Bright Minds Bioscience on its USD$35 Million Non-Brokered Private Placement - McMillan LLP
Top 4 Canadian Biotech Stocks of 2024 - Investing News Network
Bright Minds Biosciences: BMB-101's Phase 2 Trials Could Unlock Epilepsy Market Potential - Seeking Alpha
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.47% - MSN
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Short Interest Up 1,274.9% in October - MarketBeat
Steven Cohen's Strategic Acquisition of Bright Minds Biosciences Inc Shares - GuruFocus.com
Rivian Automotive Inc (NASDAQ: RIVN): Blank Check On Growth? - Stocks Register
Logos Global Management LP Acquires New Stake in Bright Minds Bi - GuruFocus.com
Bright Minds rebounds after $35M private placement - MSN
Soaring $1-handle stocks leaping into IBKR’s most-active list may point to market froth - MSN
Cormorant Asset Management's Strategic Acquisition of Bright Minds Biosciences Shares - Yahoo Finance
Bright Minds Stock Skyrockets After $35M Private Placement Amid Volatility - SpeaksLY
$DRUG 5,900% Weekly Surge Turns Attention. Cybin ($CYBN) Rallying 23% This Week In Anticipation For Major Milestones - FinanceFeeds
Bright Minds Biosciences (DRUG) Partners with Firefly Neuroscience, Resulting in Stock Surge - TipRanks
Bright Minds and Firefly Neuroscience Renew Collaboration - TipRanks
What's Going On With Bright Minds Biosciences Stock? - Benzinga
Such Is The Power Of Bright Minds Biosciences Inc (NASDAQ: DRUG) - Stocks Register
Cigna and Humana re-engage in merger talks - Yahoo! Voices
Gen Z demands improved payment options for insurance in UK - Yahoo! Voices
2 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire - Yahoo! Voices
Bright Minds, Firefly Neuroscience Shares Rise on Collaboration for Clinical Trial Analysis - MarketWatch
Bright Minds, Firefly Neuroscience to collaborate after BREAKTHROUGH study - TipRanks
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data - The Manila Times
Netflix's Third-Quarter Results Exceeded Expectations. But Is the Stock a Buy? - Yahoo! Voices
In data: Value, luxury, sportswear set to drive Turkish apparel market - Yahoo! Voices
Fuzzy’s Taco Shop announces new leadership roles - Yahoo! Voices
SB Energy’s Orion Solar Belt begins commercial operations in US - Yahoo! Voices
KIMS signs MOU with Wipro GE Healthcare for medical technologies - Yahoo! Voices
Nordic and BeeKeeperAI partner to accelerate AI clinical support systems - Yahoo! Voices
DNB Bank acquires asset manager Carnegie - Yahoo! Voices
Groww pays $160M tax as it returns to India amid a startup relocation wave - Yahoo! Voices
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.75% - MSN
FDA is said to see “path forward” for ecstasy-based drug (DRUG:NASDAQ) - Seeking Alpha
Extra Space Storage Inc. stock outperforms competitors on strong trading day - MarketWatch
Ross Stores Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Bright Minds Biosciences’ $35M Private Placement Boost - TipRanks
Bright Minds Bio soars on US$35M private placement; up 5,400% in 5 days - Mugglehead
Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results - Benzinga
Nashville Convention Center Authority board members confirmed for second term overseeing Music City Center - Yahoo! Voices
What's Going On With Bright Minds Biosciences Stock Friday? - Benzinga
Bright Minds’ stock explodes after $35M placement, pain drug news - Green Market Report
Finanzdaten der Bright Minds Biosciences Inc-Aktie (DRUG)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bright Minds Biosciences Inc-Aktie (DRUG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cormorant Asset Management, LP | 10% Owner |
Oct 15 '24 |
Buy |
5.53 |
372,591 |
2,061,574 |
825,000 |
| Cormorant Asset Management, LP | 10% Owner |
Oct 16 '24 |
Buy |
23.46 |
50,000 |
1,172,813 |
875,000 |
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):